FAU own research funding: EFI / IZKF / EAM ...
Start date : 01.06.2025
End date : 31.05.2026
Melanoma is a significant health issue. While checkpoint inhibitors (CPIs) have improved survival, therapy-resistant melanoma remains a challenge, approx. 40% of patients not responding to CPI treatments. Enhancing coadjuvant therapies combined with CPIs is needed. Clinical studies suggest that tumor peptide vaccines can reduce CPI resistance. This project aims to develop semi-personalized TAA-based immunotherapy using tumor sequencing, machine learning, and lab experiments to improve outcomes.